Abstract
G-protein-coupled receptors are desensitized by a two-step process.
In a first step, G-protein-coupled receptor kinases (GRKs) phosphorylate
agonist-activated receptors that subsequently bind to a second class
of proteins, the arrestins. GRKs can be classified into three subfamilies,
which have been implicated in various diseases. The physiological
role(s) of GRKs have been difficult to study as selective inhibitors
are not available. We have used SELEX (systematic evolution of ligands
by exponential enrichment) to develop RNA aptamers that potently
and selectively inhibit GRK2. This process has yielded an aptamer,
C13, which bound to GRK2 with a high affinity and inhibited GRK2-catalyzed
rhodopsin phosphorylation with an IC50 of 4.1 nM. Phosphorylation
of rhodopsin catalyzed by GRK5 was also inhibited, albeit with 20-fold
lower potency (IC50 of 79 nM). Furthermore, C13 reveals significant
specificity, since almost no inhibitory activity was detectable testing
it against a panel of 14 other kinases. The aptamer is two orders
of magnitude more potent than the best GRK2 inhibitors described
previously and shows high selectivity for the GRK family of protein
kinases.
Users
Please
log in to take part in the discussion (add own reviews or comments).